Apne-Scan aims to free up sleep clinic capacity

Bluefrog Design has helped to develop Apne-Scan for Apnea Tech – designed to diagnose sleep apnoea.

Apne-Scan is designed to triage patients with suspected sleep apnoea by using a Bluetooth enabled, single use device that screens for sleep apnoea by monitoring the breath pathway.

With the potential to increase capacity within busy sleep clinics, Apne-Scan enables patients to access muchneeded treatment. The device is focused on best user- centred design principals, and is a lightweight device that prioritises patient comfort.

Andy Moss, founder of Apnea Tech Ltd. praised Bluefrog Design’s professionalism and collaboration throughout the development of Apne-Scan, which he sees as a long-term partnership.

Bluefrog is proud to have supported Apnea Tech Ltd. through the product development journey in the medical sector and is looking forward to a continued collaboration going forward.

FDA grants Breakthrough Device Designation for Point-of-Care oral cancer test

Vigilant Biosciences, a developer of solutions that aid in the early detection of oral cancer, has received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its point-of-care oral cancer diagnostic.

The BeVigilant OraFusion Test determines the presence of certain biomarkers combined with artificial intelligence software for clinical risk factors. Early detection, as defined by detection in either Stage 1 or Stage 2, can lead to significantly improved outcomes with survival rates as high as 90%.

The current oral cancer survival rate is only 50% due to delayed intervention.

Bill Brodie, CEO of Vigilant Biosciences, said: “This Breakthrough Designation is a critical milestone in the review process of what we believe to be a life-saving technology. Ongoing clinical results indicate significant benefits offered to patients and allow us to continue our mission of providing a world-class early detection solution for the presence of oral cancer.”